Sruthi Arepalli, MD
Retina Specialist · Atlanta, GANPI 1659799773
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $21,270 of the $30,307 with a category attached, or 70.2%. 9 manufacturers reported payments, led by AbbVie at 34.4% of the total. 2025 is the largest year on record at $12,381, 5.3 times the $2,329 reported in 2019.
Across 49 payments — averaging $618.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$10K
- Genentech USA, Inc.$9K
- Alimera Sciences, Inc.$4K
- Eyepoint US, Inc.$4K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$1K
- Alcon$991
- plus $394 from 3 others
What the payments were for
- Consulting fees$21,27070%
- Speaking & faculty fees$4,10014%
- Travel & lodging$2,99710%
- Food & beverage$1,9406%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 5 | $10,433 |
| Genentech USA, Inc. | 8 | $9,195 |
| Alimera Sciences, Inc. | 3 | $4,124 |
| Eyepoint US, Inc. | 7 | $3,814 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 15 | $1,356 |
| Alcon | 4 | $991 |
| Bausch & Lomb Americas Inc. | 5 | $347 |
| Biogen | 1 | $27 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OZURDEX$10,275
- Iluvien$4,100
- YUTIQ$3,627
- STELLARIS PC$960
- LIGHT PIPES$960
- OPHTHALMIC INSTRUMENTS$960
- VITESSE$960
- DAILIES$435
- enVista MX60 IOL$138
- XIPERE$123
- DEXYCU$102
How this compares
Too few retina specialist providers in Georgiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 100 | $4,006 |
| Ketorolac Tromethamine | 22 | $1,014 |
| Timolol Maleate | 17 | $323 |
| Brimonidine Tartrate | 14 | $292 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 22 | $272 |
| Prednisone | 16 | $92 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Atlanta
- David Chin YeeAtlanta$816K
- Daniel OhAtlanta$58K
- James FrankAtlanta$4K
- Nihaal MehtaAtlanta$468
- Ranjit DhaliwalAugusta$18K
- Oksana DemediukAugusta$16K
- Alexander BottiniBraselton$7K
- Kareem SioufiMarietta$6K
- Dimple ModiRome$3K
- Sohail KhanAugusta$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.